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1. Introduction 
We demonstrated [l] that insulin action on glucose 
uptake into skeletal muscle is significantly reduced 
when the proteolytic liberation of kinins from 
kininogen by kallikrein was suppressed by a kallikrein 
inhibitor. A crucial role of kinin liberation has been 
demonstrated for the acceleration of glucose uptake 
which occurs during muscle work [2] and hypoxia 
[3]. Since evidence had been obtained [4] that the 
effect of kinins on glucose uptake into muscle was 
mediated via the synthesis of prostaglandins, it was 
of interest to investigate whether insulin action on 
glucose uptake into skeletal muscle of the human 
forearm might be impaired after indomethacin pre- 
treatment which prevents prostaglandin synthesis in 
man [S]. 
2. Materials and methods 
Fourteen healthy volunteers were recruited from 
medical students. All were informed about the aim 
and the risks of the study and gave their consent. 
Physical examination as well as laboratory tests 
excluded internal diseases. All the subjects fasted 
overnight and received no special premeditation. The 
catheterization procedure was detailed in [3,4]. 
Arterial and deep-venous blood samples were collected 
simultaneously at 5 mm intervals throughout 15 min 
basal period followed by a 30 min infusion period for 
chemical analysis. 
Chemical analysis was performed in 6 subjects 
294 
(group 1) during the intrabrachial-arterial infusion of 
highly purified crystalline bovine insulin (250 pU/kg 
X min in 0.2 ml physiological saline/mm) for the 
whole test period. Another 6 subjects (group 2) 
received identical insulin infusion after the oral pre- 
treatment with indomethacin Amuno@ from Sharp 
and Dohme, Munich (3 daily doses of 100 mg each 
for 2 days and another 100 mg dose 1 h prior to the 
test). The 2 groups were well comparable as to their 
age, height and weight. Three minutes after the start 
of insulin infusion, 1 mg glucose/kg body wt/min was 
infused into an anticubital vein in group 1. Forearm 
blood flow was estimated by venous-occlusion plethys- 
mography [6,7] as detailed in [4]. 
Glucose, free fatty acids and /3-hydroxybutyrate 
were determined after storage at -20°C overnight, 
acetoacetate at least within 6 h. Blood samples for gas 
analysis were taken in heparinized syringes and 
analyzed promptly. Procedure and precision of the 
tests has been given in [g] . Serum insulin was assayed 
according to a modification [9] of the Yalow-Berson 
immunoassay [ lo] , human growth hormone (HGH) 
according to [ 1 l] . Standard statistical methods were 
employed using Student’s t-test for paired and 
unpaired samples when applicable [ 121. All the mean 
values are given with the standard error of the mean 
(SEM). 
3. Results 
The arterial concentration of substrates and of 
HGH are listed in table 1. After indomethacin pre- 
treatment glucose concentration was significantly 
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Table 1 
Arterial concentrations of substrates and of human growth hormone (HGH) during the intrabrachial- 
arterial infusions of insulin (I) and insulin after indomethacin pretreatment 
Insuline 
Basald 10min 20 min 30min 
I 
II 
19.9 f 0.3 
19.6 f 0.2 
19.9 f 0.3 
19.7 f 0.2 
- 
- 
20.0 f 0.3 
19.8 * 0.2 
4.42 f 0.10 
5.28 i 0.18g 
0.610 i 0.086f 
0.617 i 0.05gf 
0.115 f. 0.018 
0.148 f 0.024 
0.068 f 0.016 
0.056 f 0.014 
- 
- 
Oxygena 
Glucoseb 
Free fatty acidsb 
fl-Hydroxybutyrateb 
Acetoacetateb 
HGHC 
4.52 + 0.10 
5.25 + 0.18g 
4.60 f 0.11 
5.40 * 0.168 
4.53 * 0.11 
5.28 f 0.18g 
I 
II 
I 
II 
0.743 * 0.098 
0.848 f 0.101 
0.687 f 0.065 
0.798 f 0.877 
0.620 i 0.081 
0.720 * 0.061 
0.120 f 0.020 
0.153 i 0.028 
I 
II 
0.125 f 0.018 
0.168 f 0.030 
0.125 i 0.018 
0.165 i 0.030 
0.074 f 0.012 
0.071 f 0.020 
0.075 f 0.017 
0.065 i 0.017 
0.075 i 0.016 
0.061 f 0.015 
I 
II 
I 
II 
7.5 f 4.1 
9.6 k4.2 
The values are given as the mean f SEM of 6 (I) and 8 (II) subjects in ml/l00 mla and in mmol/lb, 
the values for HGH as the mean i: SEM of 6 subjects in each group in ng/mlc, d from 4 determinations at 
5 mln intervals averaged for each subject, e250 MU kg body wt-‘0min -I. fSignificant at P < 0.05 to basal, 
gat P < 0.05 to I. 
higher and did not fall during the infusion of insulin 
although no glucose was infused. The arterial con- 
centrations of growth hormone were almost identical 
in both collectives. 
Forearm blood flow (FBF), arterial-deep-venous 
concentration difference of oxygen and glucose, and 
deep-venous concentration of insulin (IRI) are given 
in table 2. 
Arterial-deep-venous glucose difference rose 
continuously reaching 5times the basal value at the 
end of insulin infusion (p<O.OOS, paired t-test). After 
indomethacin pretreatment this effect of insulin was 
significantly reduced throughout the test (table 2). 
Deep-venous IRI concentrations exhibited no signif- 
icant differences between both groups. While the 
calculated uptake of oxygen was maintained, glucose 
uptake rose corresponding to the increase of arterial- 
deep-venous glucose difference as illustrated in fig.1. 
After indomethacin treatment glucose uptake was 
significantly reduced while oxygen uptake remained 
essentially unchanged. 
0 wthout 
q wth lndomethaan 
BASAL - INSULIN 
Fig.1. Glucose uptake into skeletal muscle of the forearm. The 
values were calculated from the arterial deep-venous dif- 
ferences and the corresponding blood flow rates and are 
indicated as the mean f SEM of 6 subjects in each group. The 
values for the controls have been obtained from [ 11. Insulin 
was infused into the brachial artery. (a) Indicates significant 
difference at p <0.05 as compared to basal; (b) at p< 0.05 
as compared to untreated subjects. 
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4. Discussion 
Insulin accelerated glucose uptake into skeletal 
muscle of the human forearm as described [ 13,141. 
The well-known insulin resistance occurring after 
indomethacin pretreatment [lS--171 (manifested 
by elevated glucose concentrations in the presence of 
normal insulin levels and the reduced action of insulin 
on glucose uptake into muscle) could not be attributed 
to an increase in growth hormone (table 1,2). The 
effect of indomethacin during insulin infusion could 
also not be ascribed to a smaller insulin supply 
(table.2). Furthermore, the data on oxygen uptake, 
free fatty acids and ketone bodies indicated compara- 
ble metabolic onditions in both groups and thus, 
provided likewise no explanation for the reduced 
glucose utilization after indomethacin. 
It appears therefore, that the inhibition of prosta- 
glandin biosynthesis by indomethacin isresponsible 
for the depression of insulin activity [5]. This would 
imply a participation of prostaglandins in the trans- 
lation of insulin action on glucose uptake into skeletal 
muscle. There are other findings which favour this 
view. Prostaghurdins are known to exhibit insulin- 
like activity in myocardial [18-201 and adipose 
tissue [2 1,221 . 
Furthermore, kinins, the most likely candidates 
for the muscular activity factor [2,3,23] (which them- 
selves display insulin-like activity [4,24]) are no longer 
effective ifprostaglandin synthesis blocked by indo- 
methacin [4] . Further support has come from the 
finding that prevention of endogenous kinin liberation 
by a kallikrein inhibitor also reduced the action of 
insulin on glucose uptake into the human forearm 
[ 11. That insulin, in contrast o kinins [4,25] and 
prostaglandins [26] , did not accelerate blood flow 
([13,14] table 2) would not speak against such a 
notion, since insulin exhibits its actions only in 
insulin-sensitive tissues where the hormone is bound 
to specific receptors [271. 
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